MajorAntiretroviral, HIV protease inhibitor×Glucocorticoids
Updated · Methodology
Mechanism
CYP3A4, a liver enzyme, metabolises atazanavir, and dexamethasone is a moderate inducer of this enzyme (dexamethasone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), so atazanavir levels may fall (atazanavir label, US Food and Drug Administration, FDA). Atazanavir itself inhibits CYP3A4, and ritonavir, part of the recommended atazanavir regimen, inhibits it more strongly than atazanavir (atazanavir SmPC, European Medicines Agency, EMA). CYP3A4 also metabolises dexamethasone, so human immunodeficiency virus (HIV) protease inhibitors may raise its plasma levels and reduce its clearance (AEMPS). When boosted with cobicistat, atazanavir is more sensitive to CYP3A induction than with ritonavir (atazanavir/cobicistat SmPC, EMA).
Symptoms
Lower atazanavir levels may lead to loss of its effect against the human immunodeficiency virus (HIV) and to resistance to atazanavir or ritonavir (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA). Higher corticosteroid levels, particularly with long-term use, may increase the risk of systemic effects, including Cushing's syndrome and adrenal suppression (EMA). Typical signs of Cushing's syndrome with dexamethasone are a moon face, facial plethora and truncal obesity (dexamethasone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Too rapid a dose reduction after long treatment can lead to acute adrenal insufficiency, hypotension and death (AEMPS).
Management
Consider other corticosteroids instead of dexamethasone, because dexamethasone may cause atazanavir to lose its antiviral effect (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA; atazanavir label, US Food and Drug Administration, FDA). Atazanavir is not recommended with CYP3A4 inducers. Atazanavir with ritonavir is not recommended with glucocorticoids metabolised by CYP3A4 unless the potential benefit outweighs the risk of systemic corticosteroid effects (EMA). Dexamethasone belongs to both groups (dexamethasone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The atazanavir contraindication covers strong CYP3A4 inducers (EMA), and the dexamethasone SmPC describes dexamethasone as a moderate inducer (AEMPS). The dexamethasone SmPCs advise avoiding combinations with CYP3A inhibitors unless the benefit outweighs the increased risk of systemic corticosteroid adverse reactions. If the combination is prescribed, patients are monitored for these reactions, and the dexamethasone dose can be reduced if necessary (AEMPS). The same recommendations apply if ritonavir is removed from the regimen (EMA). For atazanavir with cobicistat, the US label also advises considering other corticosteroids (atazanavir/cobicistat label, FDA). When dexamethasone is withdrawn, a slow dose reduction can minimise the risk of acute adrenal insufficiency (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Reyataz (atazanavir) prescribing information (2024)– DailyMed setid 165cff62-b284-4a27-a65d-9ec8a5bfcdd8, revisión 12/2024, secciones 4 y 7.3
- AEMPS: Ficha técnica: Dexametasona (nº registro 86123), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 86123, revisión 05/2026, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Dexametasona 4 mg (Fortecortin) (nº registro 70032), secciones 4.4 y 4.5 (2023)– AEMPS, CIMA, nº registro 70032, revisión 08/2023, secciones 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat (EU/1/15/1025), sección 4.5 (2026)– EMA, Evotaz 300 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, secciones 4.3 y 4.5
- EMA: Ficha técnica: Atazanavir, Reyataz (EU/1/03/267), sección 4.4 (2026)– EMA, Reyataz 300 mg cápsulas (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 03267008, consultada 11/2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5 (CORTICOSTEROIDES)
- FDA: Evotaz (atazanavir and cobicistat) prescribing information (2025)– FDA, DailyMed setid 83db29d7-5d85-49d6-8cb6-740473365cf8 (E.R. Squibb & Sons), version 16, revised 05/2025, sections 4 and 7.3 (Corticosteroids)